The hepatitis B e antigen suppresses IL-1β-mediated NF-κB activation in hepatocytes

Journal of Viral Hepatitis

Volumn 18, Issue 10, 2011, Pages

  Wilson, R ^a,b   Warner, N ^a   Ryan, K ^a   Selleck, L ^a   Colledge, D ^a   Rodgers, S ^a   Li, K ^c   Revill, P ^a   Locarnini, S ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

hepatitis B e antigen; hepatitis B virus; interleukin 1; NF B activation; precore protein; TIR signalling

Indexed keywords

CORE PROTEIN; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PROTEIN P21; PROTEIN P22;

ARTICLE; CYTOKINE PRODUCTION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; KIDNEY CELL CULTURE; LIVER CELL CULTURE; PRIORITY JOURNAL; VIRUS IMMUNITY;

ARTIFICIAL GENE FUSION; CELL LINE; EPITHELIAL CELLS; GENES, REPORTER; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; IMMUNE EVASION; INTERLEUKIN-1BETA; LUCIFERASES; NF-KAPPA B;

EID: 80052846666     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01484.x     Document Type: Article

References (38)

1. Seeger C, Mason W,. Hepatitis B Virus Biology. Microbiol Mol Biol Rev 2000; 64 (1): 51-68. (Pubitemid 30143840)
2. Chisari F, Ferrari C, Mondelli M,. Hepatitis B virus structure and biology. Microb Pathog 1989; 6: 3111-3325.
3. Heise T, Sommer G, Ruemann K, Meyer I, Will H, Schaal H., The hepatitis B virus RPE contains a splicing regulatory element. Nucleic Acids Res 2006; 34 (1): 353-363. (Pubitemid 43160058)
4. Garcia PD, Ou J-H, Rutter WJ, Walter P,. Targeting of the Hepatitis B virus precore protein to the endoplasmic reticulum membrane: after signal peptide cleavage translocation can be aborted and the product released into the cytoplasm. J Cell Biol 1988; 106: 1093-1104.
5. Revill P, Yuen L, Walsh R, Perrault M, Locarnini S, Kramvis A,. Bioinformatic analysis of the Hepadnavirus e-Antigen and its precursor identifies remarkable sequence conservation in all Orthohepadnaviruses. J Med Virol 2010; 82: 104-115.
6. Beck J, Nassal M,. Hepatitis B virus replication. World J Gastroenterol 2007; 13 (1): 48-64. (Pubitemid 46165462)
7. Brunetto M, Giarin M, Oliveri F, et al,. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991; 88: 4186-4190. (Pubitemid 21914504)
8. Milich DR, Chen MK, Hughes J, Jones J,. The secreted Hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160: 2013-2021. (Pubitemid 28106492)
9. Bowie AG, O'Neill LAJ,. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 2000; 67: 508-514.
10. O'Neill LAJ, Bowie AG,. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353-364. (Pubitemid 46674493)
11. Akira S, Takeda K,. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511. (Pubitemid 38931765)
12. Arend WP, Palmer G, Gabay C,. IL-1, IL-18 and IL-33 families of cytokines. Immunol Rev 2008; 223 (1): 20-38. (Pubitemid 351986169)
13. Karin M, Lin A,. NF-kB at the crossroads of life and death. Nat Immunol 2002; 3 (3): 221-227.
14. Priess S, Thompson A, Chen X, et al., Characterization of the innate immune signalling pathways in hepatocyte cell lines. J Viral Hepat 2008; 15 (12): 888-900.
15. Thompson A, Colledge D, Rodgers S, et al,. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther 2009; 14: 797-808.
16. Visvanathan V, Skinner N, Thompson A, et al,. Regulation of Toll-like receptor-2 expression in chronic Hepatitis B by the precore protein. Hepatology 2007; 45 (1): 102-110. (Pubitemid 46150869)
17. Ikeda M, Sugiyama K, Mizutani T, et al,. Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. Virus Res 1998; 56: 157-167. (Pubitemid 28414407)
18. Noguchi M, Hiroshashi S,. Cell lines from non-neoplastic liver and hepatocellular carcinoma tissue from a single patient. In Vitro Cell Dev Biol Anim 1996; 32 (3): 135-137.
19. Warner N, Locarnini S,. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48 (1): 88-98. (Pubitemid 351975534)
20. Chin R, Shaw T, Torresi J, et al,. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45 (9): 2495-2501. (Pubitemid 32801901)
21. Warner N, Locarnini S, Kuiper M, et al., The rtL80I Substitution in the Hepatitis B Virus Polymerase is Associated with Lamivudine Resistance and Enhanced Viral Replication in Vitro. Antimicrob Agents Chemother 2007; 51 (7): 2285-2292. (Pubitemid 47047302)
22. Chen RY, Edwards R, Shaw T, et al,. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37 (1): 27-35. (Pubitemid 36042141)
23. Fried MW, Piratvisuth T, Lau G, et al.,. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47 (2): 428-434. (Pubitemid 351280710)
24. Doria M, Klein N, Lucito R, Schneider R., The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J 1995; 14 (19): 4747-4757.
25. Abe T, Kaname Y, Hamamoto I, et al,. Hepatitis C virus nonstructural protein 5A modulates the Toll-like receptor-MyD88-depedent signaling pathway in macrophage cell lines. J Virol 2007; 81 (17): 8953-8966. (Pubitemid 47311439)
26. Kaukinen P, Sillanpaa M, Kotenko S, et al., Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression. Virology J 2006; 3:(66).
27. Li K, Foy E, Ferreon J, et al,. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. PNAS 2005; 102 (8): 2992-2997. (Pubitemid 40299904)
28. Meylan E, Curran J, Hofmann K, et al,. Cardif is an adaptor protein in the RIG-1 antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 1167-1172. (Pubitemid 41509355)
29. Otsuka M, Kato N, Moriyama M, et al,. Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses. Hepatology 2005; 41 (5): 1004-1012. (Pubitemid 40593908)
30. Bowie AG, Kiss-Toth E, Symons J, Smith G, Dower S, O'Neill L,. A46R and A52R from vaccinia virus are antagonists of host IL-1 and Toll-like receptor signaling. PNAS 2000; 97 (18): 10162-10167.
31. Stack J, Haga I, Schroder M, et al,. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 2005; 201 (6): 1007-1018. (Pubitemid 40524469)
32. DiPerna G, Stack J, Bowie AG, et al,. Poxvirus protein N1L targets the I-kB kinase complex, inhibits signaling to NF-kB by the Tumor Necrosis Factor superfamily of receptors, and inhibits NF-kB anf IRF3 signaling by Toll-like receptors. J Biol Chem 2004; 279 (35): 36570-36578. (Pubitemid 39129000)
33. Oshansky CM, Krunkosky T, Barber J, Jones L, Tripp RA,. Respiratory syncytial virus proteins modulate suppressors of cytokine signalling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol 2009; 22 (3): 147-161.
34. Wu J, Meng Z, Jian M, et al,. Hepatitis B virus suppresses Toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009; 49 (4): 1132-1140.
35. Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schroder CH,. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J Virol 1993; 67 (7): 3756-3762. (Pubitemid 23180696)
36. Scaglioni PP, Melegari M, Wands JR,. Posttranscriptional regulation of hepatitis B virus by the precore protein. J Virol 1997; 71 (1): 345-353. (Pubitemid 26412298)
37. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A,. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the Toll-like receptor signalling pathway. J Hepatol 2011; doi:.
38. Ait-goughoulte M, Lucifora J, Zoulim F, Durantel D,. Innate antiviral immune responses to hepatitis B virus. Viruses 2010; 2: 1394-1410.